Vimarsana
Biggest News Aggregation in the World

Page 2 - Clinical Testing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Testing Today - Breaking & Trending Today

SLS' new chemicals catalogue is here Labmate Online - Vimarsana News

SLS' new chemicals catalogue is here Labmate Online

Back by popular demand SLS are proud to introduce the second edition of their ever-useful chemicals catalogue. Click to read more...

COVID in Boise wastewater is highest it's been in 2 years. This is what to know. - Vimarsana News

COVID in Boise wastewater is highest it's been in 2 years. This is what to know.

A new COVID-19 variant is responsible for over half of infections in Boise, wastewater data shows of latest surge.

Source: yahoo.com
Itchy skin? Possible atopic dermatitis? Lavender essential oil might be just what you're looking for - Vimarsana News

Itchy skin? Possible atopic dermatitis? Lavender essential oil might be just what you're looking for

Researchers demonstrate that lavender essential oils, particularly linalyl acetate, effectively suppress atopic dermatitis without skin sensitization, offering a natural, accessible treatment option.

Cancer Cachexia Market to Hit USD 3.6 billion by 2031, at a CAGR 4.7% | Says Transparency Market Research, Inc. - Vimarsana News

Cancer Cachexia Market to Hit USD 3.6 billion by 2031, at a CAGR 4.7% | Says Transparency Market Research, Inc.

Progress in the market is also being aided by an increase in research on non-steroidal anti-inflammatory drugs (NSAIDs) and a rise in patient knowledge of the advantages of drugs.Wilmington, Delaware, United States, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global cancer cachexia market was projected to attain US$ 2.2 billion in 2022. It is anticipated to garner a 4.7% CAGR from 2023 to 2031. By 2031, the market is likely to attain US$ 3.6 billion by 2031. Researc

Source: yahoo.com
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm's INI-822 for metabolic liver disease treatment now in clinical testing - Vimarsana News

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm's INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH).